Streetwise Reports' Article Archives — December 2019 back to current month (127)
It will produce the oil to be sold at its flagship asset in the Maranon Basin.
The company's successes in this regard align with its aim to capitalize on its organic growth and land position.
Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina.
Beware the Stock Market (12/31/2019)
Sector expert Bob Moriarty takes a look at drivers in the bull market and sees a bear in the wings.
Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Maurice Jackson of Proven and Probable interviews Andy Schectman of Miles Franklin Precious Metals Investments about the implications of monetary policies being implemented by central banks worldwide, and about the state of the U.S. economy.
Gold Market Update: Metal Up, Dollar Down (12/30/2019)
Technical expert Clive Maund charts the reasons the precious metals have entered a bull market.
Silver Market Update: A Bullish Setup in Place (12/30/2019)
Technical analyst Clive Maund charts the end-of-the-year status of the silver market.
A Short Update on Irving, Lion One and Novo (12/29/2019)
Bob Moriarty of 321gold unwraps the people and projects he believes makes these companies compelling investments.
The status and review of a few aspects of this project are provided in a Canaccord Genuity report.
The company aims to conduct pilot production testing in Q1/20.
Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results in Q1/20.
The latest clinical trial results and next step are reviewed in an H.C. Wainwright & Co. report.
Mine operations and preproduction work continue nonstop, the company stated.
The Canadian junior will stay focused on two primary targets.
The Ins and Outs of Making a Private Placement (12/27/2019)
In part two of his series, 'All About Private Placements,' Maurice Jackson of Proven and Probable solicits details on how to find private placements, and then how to process forms for those placements, from Tekoa Da Silva, a financial advisor with Sprott USA.
The assays are presented and reviewed in an Echelon Wealth Partners report.
Highlights of that document and the mine ramp-up are presented in a BMO Capital Markets report.
Shares of Israel-based renewable energy firm Ellomay Capital got a jolt today after the firm released details of the development plans for photovoltaic projects in Italy with aggregate capacity of 265 megawatts.
The favorable metrics of the transaction are discussed in a Raymond James report.
The highlights and benefits of the transaction are provided in a Haywood report.
The latest findings are reviewed in an Echelon Wealth Partners report.
Shares of Microbot Medical traded 70% higher after the company reported that in January 2020 it will unveil the world's first fully disposable robotic system for endovascular procedures. The firm claims that its breakthrough technology features compact design, remote operation capabilities and an integrated "One & Done" tool to democratize endovascular procedures.
For full ownership, the earn-in period is two years.
The key business and investment points are presented in a ROTH Capital Partners report.
Fracking Imminent for Orogrande Basin Well (12/23/2019)
The purpose is to show its potential for commercial oil production.
This achievement represents another step toward making augmented reality technology universally accessible.
Thibaut Lepouttre of Caesars Report examines how this Canadian company intends to improve on the 440,000-ounce gold-equivalent resource at its flagship project.
After receiving a favorable ruling on the NRC license, its focus shifts to project economics.
Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTAŽ (lumateperone) drug for the treatment of schizophrenia in adults.
Shares of Apache Corp. traded 16% higher today after the company reported that it has formed a joint venture with Total SA of France to explore and develop Block 58 offshore Suriname.
The purchase price for the company is 4.5 million shares.
The company will start the work there in either late winter or early spring 2020.
Agreements are for one lease, one option and two sales deals.
The program goal is to improve care access and health outcomes among residents of Australia's remote and rural areas.
Nevada Miner Reaches Milestone as Production Begins (12/21/2019)
Maurice Jackson of Proven and Probable discusses future plans with this copper company's senior VP of Operations.
Shares of NewLink Genetics got a boost today after the firm reported that the FDA approved its ERVEBO V920 vaccine used in the treatment of Zaire Ebola virus. The company's shares set a new 52-week high price in mid-morning trading.
GFG Waits for Barn-Burning News (12/20/2019)
Bob Moriarty of 321gold provides an update on this junior miner.
One-Week Sale on Aurania Shares (12/20/2019)
Bob Moriarty of 321gold describes the investment opportunity in this company.
The developer will initially deploy its product at Banc of California stadium in January.
The firm states the new targets could "contribute to the multi-generational life" of the district.
The results suggest possible geologic scenarios that require further testing.
Mineralization demonstrated there consists of platinum group elements, nickel, copper and cobalt.
The explorer is to sell its net profit interest in a Nevada property to a royalty company.
Royalties Face Mine Problems and Tax Bills (12/19/2019)
Money manager Adrian Day looks at two top royalty companies, both with a changing of the guard at the top, both with other important developments, plus he lists some companies he sees as buys.
Shares of Paratek Pharmaceuticals traded 40% higher today after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax.
The requirements include, among others, trials of the company's livestock feed additive.
Bob Moriarty of 321gold takes a look at the Daily Sentiment Index for palladium.
Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 million over three years.
The Critical Investor sits down with Joe Grosso, CEO of Golden Arrow Resources, to discuss the company's exploration plans for the new year.
The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report.
Biopharma 'Keeps Executing and Securing Milestones' (12/17/2019)
The company's latest achievement and partnership potential are addressed in a ROTH Capital Partners report.
News Flash! (12/17/2019)
Sector expert Michael Ballanger asserts that statements by American financial and political leaders are little more than market manipulations.
The firm is finishing state mining agency requirements, targeting completion of those by end of January 2020.
Miner Starts IP Survey on Nevada Project (12/17/2019)
The company states the aim is to better define the gold trend.
The Canadian company attributes this achievement to increased sales in each of its business segments.
This is the first step toward a binding, definitive agreement between the two companies.
The new customer intends to use two of the company's platforms for marketing and education purposes.
Shares of Tallgrass Energy LP traded 20% higher after the firm advised that it entered into a definitive merger agreement with Blackstone Infrastructure Partners to acquire all of the company's publicly held outstanding class A shares for $22.45 per share in cash.
These findings are from the ongoing 200,000m drill testing at its Ontario project.
Nevada Copper Delivers Copper Now (12/17/2019)
Bob Moriarty of 321gold discusses recent copper price moves along with those of a new copper producer.
Recent drill results from both assets are provided in a ROTH Capital Partners report.
The company has announced two new initiatives to propel growth.
This development is part of the company's recently expanded contract with Walther.
Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application filing in H2/20.
Maurice Jackson of Proven and Probable speaks with Dr. John-Mark Staude, CEO of Riverside Resources, about his company's recent exploration efforts at its Oakes gold project in Ontario and what lies ahead in the new year.
The company reports the assays for its campaign's last two drill holes for its Canadian REE project.
The maiden order comes on the heels of the country approving use of the product there.
The Vancouver-based company debuts its premium brand dried flower in Alberta.
Firm to Launch 3D Augmented Reality Capture App (12/13/2019)
Anyone with the product and a smartphone will be able to create 3D models of 2D objects.
Tim Johnson, CEO of Granite Creek Copper, sits down with Maurice Jackson of Proven and Probable to discuss the copper market, his company's exploration plans in the Yukon and its recent purchase of a 30% stake in its neighbor.
Sarepta Therapeutics shares traded 35% higher after the firm reported that the FDA approved its second RNA exon-skipping treatment drug VYONDYS 53 injection for the treatment of Duchenne's Muscular Dystrophy in patients amenable to skipping Exon 53.
STACK Agreement 'Positive' for Area Operator (12/12/2019)
The deal details are relayed in a ROTH Capital Partners report.
Technical analyst Clive Maund looks at recent moves in gold and their correlation to the dollar.
Silver Remains in 'Corrective Downtrend' (12/12/2019)
Technical analyst Clive Maund charts the longer term picture for silver.
Assertio Therapeutics' shares rose 50% today after the firm reported that it has agreed to sell all rights to its Gralise drug used in the treatment of pain from shingles to Alvogen for $127.5 million. The transaction is expected to close in January 2020.
Bob Moriarty of 321gold looks at the LREO explorer's drill results at its Canadian project.
The Critical Investor sits down with Avrupa Minerals CEO Paul Kuhn to discuss plans for the company's Alvalade project in Portugal in light of the recent earn-in agreement with Mubadala Investment Company and Trafigura.
Royalty Firm to Sell Nevada Asset (12/11/2019)
The consideration for the project is $250,000 in cash and a 2% net smelter return royalty on the claims.
Recruiter.com Doubles Network Membership Since July (12/11/2019)
The company expects to continue this growth in the near term.
This development aligns with the firm's goal of dominating key multibillion dollar business segments.
Recent company announcements are discussed in a Pareto Securities report.
The basis of Haywood's investment thesis for this Canadian company is shared in a recent report.
Proteostasis Therapeutics' shares traded higher today after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-2020, and potential for a Marketing Authorization Application in 2021.
The details, finances and impact of the transaction are discussed in a CIBC report.
Peter Epstein of Epstein Research profiles a company that is reinventing itself as moderately diversified battery metals company.
Company Extends REE Mineralization at Canada Project (12/10/2019)
Consequently, additional drill testing is warranted in the specific host zone.
Oil & Gas Firm Provides Update on Exploration Well (12/10/2019)
Drill testing leads to decision to abandon the well.
Silver: The HARD Look (12/10/2019)
Precious metals expert Michael Ballanger takes a look at the factors behind silver's recent price decline.
Shares of Avid Bioservices traded higher today, reaching a new 52-week high, after the firm reported Q2/20 earnings and reaffirmed its revenue guidance for Full-Year 2020.
How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note.
The two companies are advancing adjoining projects in the Yukon.
ArQule Inc. shares traded more than 100% higher today after the company entered into definitive agreement to be acquired by a Merck subsidiary company for $20 per share. The deal is valued at $2.7 billion and is expected to close in the early part of Q1/20.
Andrew Bowering, president of Prime Mining, talks with Maurice Jackson of Proven and Probable about his company's plans to fast track its gold project.
The report validates the Colorado-based company's strategy.
Now, the company has the green light to sell this product in eight countries.
The Canadian company announced a $21 million budget and aims to complete the expansion by year-end 2020.
Explorer Gathers Data on Quebec Gold Property (12/06/2019)
Regional geology, mineral showings, historical drill results and magnetic survey results are among the information obtained.
Explorer Options Majority Interest in Gold Project (12/06/2019)
Incubating and monetizing assets are among the company's strategic objectives.
The gold-silver company continues to advance the asset.
A new advancement in bladder-related endoscopic surgery is endorsed and de-risked.
Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif.
The rationale for investing in this company is provided in a Pareto Securities report.
Jay Taylor of J. Taylor's Gold, Energy & Tech Stocks examines the prospects of a company working in the exploration and development of Larder gold deposits along the Cadillac-Larder Lake Fault in Ontario.
The firm will now provide its Web-based, three-dimensional, augmented reality service to the client.
Shares of Aurinia Pharmaceuticals traded much higher today after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20.
Immuno-Oncology Firm Expands Agreement with AbbVie (12/04/2019)
The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report.
The report outlines a development plan for the project.
Explorer to Sell Interest in Nevada Gold Project (12/04/2019)
In the arrangement, the company will garner a 1% net smelter return royalty.
Company Vies for New Brunswick Cannabis Contract (12/04/2019)
The opportunity is one of the largest in retail cannabis in Canada.
The $6 million facility is available to the Vancouver-based firm until Nov. 29, 2021.
To start, the company will introduce its premium brand of dried flower there.
Increased sales spurred the growth during the month.
Gold Company's Sale of Colombia Project Closes (12/04/2019)
The company will use the proceeds to explore its Nevada asset.
Daniel Carlson of Tailwinds Research initiates coverage on this clinical-stage biotech whose drug candidate works to strengthen the innate immune system.
Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia.
The transaction is in line with the Vancouver-based company's business model.
The company believes the pairing should multiply the number of online sales that result from an augmented reality component.
A site visit to this company's project generated optimism in James Kwantes of Resource Opportunities.
Ralph Aldis, portfolio manager at U.S. Global Investors, in this interview with Streetwise Reports, looks back at trends in 2019 and looks ahead to what we may expect in the precious metals in 2020; he also discusses the top performers in the precious metals fund that he manages.
Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study.
First Vanadium CEO Paul Cowley speaks with Peter Epstein of Epstein Research about the state of the vanadium market and his company's plans to explore the newly found gold target on the Carlin Trend in Nevada.
Big Picture Outlook: Seat Belts Tightened (12/02/2019)
Sector expert Michael Ballanger offers his latest insights into the markets and his investment strategy as 2019 winds down.
An Inside Look at Private Placements (12/02/2019)
Sector expert Maurice Jackson begins a four-part series on private placements with a conversation with Tekoa Da Silva of Sprott USA.
Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases.
Riverside Resources Takes on New Project in Ontario (12/02/2019)
Freeman Smith, VP of exploration at Riverside Resources, speaks to Maurice Jackson of Proven and Probable about his company's exploration plans for its newest project in Ontario.
Bob Moriarty of 321gold discusses the Indonesian government's actions in the nickel market and how they might affect a company with a project in Norway.
|"NTAR's business is still growing well on the e-commerce and AR sides."|
|"The drills are still turning, and GBR has plenty of cash."|
|"SEA stock should do well in the coming bull market."|
|"TRCH debt holders converted the obligations into a working interest."|
|"PVG's Brucejack continues to deliver strong free cash flows."|